Theravance Biopharma (NASDAQ:TBPH) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a report released on Wednesday morning, BidAskClub reports.

Separately, Piper Jaffray Companies set a $55.00 price target on shares of Theravance Biopharma and gave the stock a buy rating in a report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $44.25.

NASDAQ TBPH opened at $21.26 on Wednesday. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48. The stock has a market capitalization of $1.21 billion, a PE ratio of -5.33 and a beta of 1.75. The firm has a 50 day moving average of $18.68 and a two-hundred day moving average of $21.23.



Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.50. Theravance Biopharma had a negative net margin of 369.67% and a negative return on equity of 2,631.15%. The company had revenue of $26.15 million during the quarter, compared to analysts’ expectations of $13.92 million. Sell-side analysts predict that Theravance Biopharma will post -4.28 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. SG Americas Securities LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $156,000. CWM Advisors LLC acquired a new position in Theravance Biopharma during the 2nd quarter worth approximately $167,000. BNP Paribas Arbitrage SA grew its holdings in Theravance Biopharma by 882.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 8,951 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $254,000. Finally, DekaBank Deutsche Girozentrale grew its holdings in Theravance Biopharma by 64.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 7,500 shares in the last quarter. Institutional investors own 83.83% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Story: Coverage Ratio

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.